

Paula Annunziato, MD

Vice President, Vaccine Clinical Development

Paula Annunziato serves as Vice President and Therapeutic Area Head for Vaccine Clinical Development.

Paula joined Merck Research Laboratories in August 2002 as Director, Biologics and Vaccine Clinical Research. During her career at Merck, Paula has been responsible for the Zostavax and Gardasil Product Development Teams, as well as the Pediatric Vaccines and the Adult Vaccines Sections.

Prior to joining Merck, Paula was Associate Professor of Clinical Pediatrics at Columbia University College of Physicians and Surgeons and a member of the Division of Pediatric Infectious Diseases. During her time at Columbia University, her research focused on latency and reactivation of the varicella zoster virus (VZV).

Paula received her Medical Degree from the University of Texas Health Science Center in San Antonio, Texas. She completed her pediatric residency at the Schneider Children's Hospital/Long Island Jewish Medical Center in New Hyde Park, New York, and her Pediatric Infectious Diseases fellowship at the University of Rochester in Rochester, New York.



Eliav Barr, MD

Senior Vice President

Global Medical Affairs

Eliav Barr is Senior Vice President and Head of Global Medical and Scientific Affairs at Merck Research Laboratories in West Point, PA. In this capacity, he is responsible for MRL's scientific exchange and medical communications function.

Prior to his current role, Eliav was Senior Vice President in charge of global clinical development of preventative/treatment approaches to infectious diseases at Merck. Eliav was also previously Therapeutic Area Head for Infectious Diseases and managed product development teams in Oncology and Infectious Disease.

Eliav joined Merck in 1995, and soon after developed and implemented the development strategy for the program. The program resulted in the first demonstration that prophylactic administration of a vaccine targeting HPV types 6, 11, 16, and 18 (Gardasil) is highly effective in reducing cervical, vulvar, and vaginal cancer risk and genital wart rates caused by these types. He also initiated the development of Gardasil 9, Merck's next generation 9-valent HPV vaccine.

Eliav received his Bachelor's from Penn State University and his Medical Degree from the Jefferson Medical College. He completed an Internal Medicine residency and a Cardiology Fellowship at Johns Hopkins. He subsequently pursued post-doctoral training at the University of Michigan and was on faculty at the University of Chicago.



Jill DeSimone

Senior Vice President US & Latin America Oncology

Jill DeSimone is a Senior Vice President at Merck, leading the US and Latin American Oncology teams.

Jill's prior experience included holding several senior leadership roles at Bristol Myers Squibb, leading the US Virology and Oncology business units. At Bristol Myers Squibb Oncology, she led the launches of several major products to help transform cancer care. Just prior to joining Merck, Jill ran the global Women's Health division at Teva Pharmaceutical, which was the first global business unit within Teva specialty brands.

For nearly a decade, Jill was a Sponsor of the Rutgers University PharmD Fellowship Program, through which more than 100 fellows were trained in more than a dozen functional areas. She currently serves on the board of Industry Pharmacy Organization to continue to support pharmacists. Jill also serves on several boards, including the American Lung Association of Mid-Atlantic.

Jill received her BS in Pharmacy from Northeastern University. She also completed the Executive Development program from the Wharton School of the University of Pennsylvania.



Nicholas Kartsonis, MD

Senior Vice President, Clinical Research Infectious Diseases / Vaccines

Nick Kartsonis serves as Senior Vice President of Clinical Research for Infectious Diseases and Vaccines.

Prior to his current role, Nick was Vice President within the Clinical Research group in the Infectious Diseases Department at Merck Research Laboratories. He also previously served as the Section Head within MRL Clinical Research for antibacterials, antifungals and non-hepatology viruses.

Nick joined MRL as an Associate Director in the Infectious Diseases / Vaccines Clinical Research Department in 2000. He was actively involved with the clinical development program for caspofungin (Cancidas, MK-0991), assuming leadership for both the Candida development program and the pediatric development program for caspofungin. He played an instrumental role in obtaining the approval of caspofungin for all four of its indications and approval in pediatric patients. He also chaired the Product Development Team for Cancidas for 7 years.

Nick received his MD from Emory University School of Medicine. After he completed training in internal medicine at Massachusetts General Hospital, he completed his subspecialty training in Infectious Diseases at the Harvard Partners System (combined MGH and Brigham and Women's Hospital).



Deepak Khanna

Senior Vice President President, EMEAC Oncology

Deepak Khanna is Senior Vice President and President of EMEAC Oncology responsible for commercial operations for the oncology business across Europe, Middle-East, Africa and Canada.

Prior to this role, Deepak was Senior Vice President and Managing Director of MSD UK and Ireland from 2009-2013, which included the integration of MSD with Schering-Plough. Alongside this role, he served as President of the Association of the British Pharmaceutical Industry, and was previously Chair of the American Pharmaceutical Group.

Deepak began his career at Merck in 1988 in field sales and held positions of increasing responsibility within the US Human Health Division. In 1996, Deepak joined the Worldwide Human Health Division, working with rheumatology products. He later assumed responsibility for the marketing planning activities for early stage central nervous system products. He rejoined the US Human Health Division in 2001 and assumed leadership responsibilities of the Migraine Franchise Business Group. In 2003, he was promoted to Vice President of the Atherosclerosis Franchise Business Group. In 2006, Deepak assumed responsibility as Senior Vice President and General Manager of the Merck/Schering-Plough joint venture.

Deepak received his MBA in Marketing from Santa Clara University and his BS in Biochemistry and Economics from the University of California, Berkeley.



Michael Kress, PhD

Senior Vice President Process R&D

Mike Kress serves as Senior Vice President of Process R&D, leading activities across the small molecule, biologics and vaccines modalities.

Prior to his current role, Mike held a series of roles of increasing responsibility at Merck, including Executive Director of Pharmaceutical Development and Vice President of Pharmaceutical Research and Development. During his tenure within drug product development, Mike supported a number of key development programs and product launches, including Janumet XR, Belsomra, and Zepatier.

Previously, Mike was Senior Director of Worldwide Process Research at Cephalon. While at Cephalon, Mike's research was focused on the enantioselective Kagan oxidation of prochiral sulfides, and efficient manufacturing routes to statins-like PKC inhibitors. He also previously served as Senior Research Chemist within the Merck Process Research group.

Mike received his PhD in Synthetic Chemistry from Harvard University and his BS in Chemistry from The Pennsylvania State University. He is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the Innovation and Quality Consortia.



Teri Loxam

Senior Vice President, Investor Relations & Global Communications

Teri Loxam is Senior Vice President of Investor Relations and Global Communications at Merck. In her role, Teri leads the company's investment community interactions as well as internal and external communications efforts globally.

Teri joined Merck in August 2015 to lead Investor Relations, with responsibility for representing the Company to the global investment community, including shaping shareholders' understanding of Merck's history, strategy, financials, product performance and future direction. In January 2018, Teri added responsibility for Global Communications, including corporate and financial media relations, product communications, public affairs and employee communications.

Prior to Merck, Teri served as Vice President, Investor Relations, for IMAX Corporation, where she reshaped the entertainment company's investor strategy. Previously, Teri spent more than a decade at Bristol-Myers Squibb, serving in a variety of functions including Investor Relations, Strategic Planning and Treasury.

Teri started her career as a marine biologist and worked at Sea World of San Diego for several years before transitioning into business. Teri holds an MBA from the University of California at Irvine and Bachelor of Science degree from the University of Victoria in Canada. Teri is an Advisory Board Member for CECP SII and IPR and is a member of Arthur Page Society.



John Markels, PhD

President

Merck Vaccines

John Markels serves as President of Merck Vaccines.

In his current role, John aims to drive a dramatic increase in the reach and public health impact of vaccines by leading an integrated team across Merck dedicated to discovery and development, supply and access, and global marketing and long-term strategy across the portfolio. John previously served as President of Latin America, where he successfully led Merck's business across the region to strong double-digit growth.

Prior to his roles in Merck's Commercial Division, John had a long career in manufacturing, with senior roles in both the Science and Technology and Operations organizations. Most recently, he was Senior Vice President of Emerging Markets in the Merck Manufacturing Division, with responsibility for manufacturing sites in Latin America and Asia Pacific as well as business development, alliance management, and supply chain. Over the course of his career, he has lived and worked in both Europe and Latin America as well as the US.

John received his PhD in Chemical Engineering from the University of California, Berkeley and his BS in Chemical Engineering from the University of Delaware.



Emma Parmee, DPhil

Vice President

Head of Discovery Chemistry

Emma Parmee serves as Head of Discovery Chemistry at Merck Research Labs.

Emma moved to Merck's West Point facility in 2010, where she held roles of increasing responsibility. Most recently, she led the Chemistry Capabilities and Screening Group, and previously served as Head of the Exploratory Chemistry group.

Prior to her time in West Point, Emma was located in Rahway, NJ, where she worked for nearly eighteen years in Cardiometabolic areas and contributed to several projects which demonstrated clinical POC including the beta 3 agonist and the glucagon receptor antagonist programs. She also worked on the DPP-4 inhibitor project and contributed to the discovery of Januvia, for which she was awarded the Thomas Alva Edison Patent Award from the R&D Council of NJ and the SCI Gordon E. Moore Medal for Innovation. She is also the recipient of the 2018 ACS Medicinal Chemistry Division Award and was inducted into the ACS Division of Medicinal Chemistry Hall of Fame in 2018. Her work has led to more than forty issued U.S. patents and over fifty publications in peer-reviewed journals.

Emma obtained her DPhil at the University of Oxford and completed a NATO postdoctoral fellowship at MIT.



Joseph Romanelli

President MSD China

Joe Romanelli serves as President of MSD China, responsible for the company's business operations in the country.

In this position, Joe has overseen the transformation of the organization which has resulted in industry leading growth. Based on his efforts to accelerate new product launches and expand access to innovative products, he was named as a "Top Pharmaceutical Leader of the Year" by the 2019 National Healthy China Forum.

Prior to his current role, Joe served in multiple roles of increasing responsibility across different divisions within the organization. Most recently he was the Cluster Lead for the Taiwan and Hong Kong markets. Prior to this role, Joe was the Vice President of Investor Relations.

Joe started his career in 1996 within MSD's manufacturing division, serving as a Bio-Technician and Manufacturing Supervisor. In 1999, he moved to the Human Health organization where he held roles of increasing responsibility in sales management, medical affairs, and country operations. Before moving to leadership roles in finance and international markets, he supported the President of Human Health for the company's overall commercial strategy and planning as Chief of Staff.

Joe received his MBA from Fordham University and his BS in Biological Sciences from the University of Delaware.



Eric Rubin, MD

Senior Vice President & Therapeutic Area Head Oncology Early Development

Eric Rubin serves as Senior Vice President and Therapeutic Area Head for Oncology Early Development.

Eric has focused on cancer drug development for over 25 years, initially as a faculty member at the Dana-Farber Cancer Institute, then as Director of the Investigational Therapeutics Division at the Cancer Institute of New Jersey. In 2008, he was recruited to Merck to lead the clinical oncology development team. Under his leadership, the clinical oncology group underwent a transformational change in an effort to realize the potential of cancer immunotherapy.

Eric has authored over 100 original, peer-reviewed publications and book chapters related to oncology translational research, clinical trials and drug development. He has served frequently as a member of National Cancer Institute and American Cancer Society study sections, as well as on program committees for the American Association of Cancer Research and the American Society of Clinical Oncology. He is a co-chair of the Cancer Steering Committee of the Biomarkers Consortium, Foundation of the National Institute of Health, and a member of the Science Policy and Governmental Affairs Committee for AACR.

Eric received his MD from University of South Florida, and his BS in Mathematics and Biology from Tulane University.

